Teachers Retirement System of The State of Kentucky trimmed its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 30.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,786 shares of the biopharmaceutical company’s stock after selling 14,294 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in TG Therapeutics were worth $1,829,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of TGTX. Morse Asset Management Inc acquired a new stake in shares of TG Therapeutics in the third quarter valued at approximately $29,000. Bessemer Group Inc. lifted its holdings in TG Therapeutics by 119.3% during the 3rd quarter. Bessemer Group Inc. now owns 290,660 shares of the biopharmaceutical company’s stock valued at $16,213,000 after purchasing an additional 158,105 shares during the last quarter. Virtus Advisers LLC increased its holdings in shares of TG Therapeutics by 25.1% in the third quarter. Virtus Advisers LLC now owns 9,138 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 1,836 shares during the last quarter. ACT Capital Partners L.P. acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth about $13,231,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of TG Therapeutics by 2.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 309,498 shares of the biopharmaceutical company’s stock worth $17,264,000 after buying an additional 8,183 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.
TG Therapeutics Stock Performance
TG Therapeutics stock opened at $64.88 on Friday. The business has a 50 day moving average of $57.39 and a 200-day moving average of $46.02. The company has a market capitalization of $9.81 billion, a P/E ratio of 98.30, a P/E/G ratio of 5.21 and a beta of 1.89. TG Therapeutics, Inc. has a 1 year low of $26.76 and a 1 year high of $68.03. The company has a debt-to-equity ratio of 1.30, a current ratio of 4.50 and a quick ratio of 3.75.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.01). The business had revenue of $259.94 million for the quarter, compared to the consensus estimate of $245.47 million. TG Therapeutics had a net margin of 11.81% and a return on equity of 18.82%. TG Therapeutics’s revenue was up 60.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.43 EPS. On average, equities research analysts predict that TG Therapeutics, Inc. will post 1.10 earnings per share for the current year.
Insider Activity
In related news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the transaction, the director directly owned 168,640 shares of the company’s stock, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.87% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. Weiss Ratings upgraded shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, November 4th. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 14th. B. Riley Financial raised their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. JPMorgan Chase & Co. increased their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Zacks Research raised TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.
TG Therapeutics Profile
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
Recommended Stories
- Five stocks we like better than TG Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
